Beyond Air Inc (XAIR)

Currency in USD
0.519
-0.051(-8.89%)
Real-time Data·
Trading near 52-week Low
XAIR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.4980.570
52 wk Range
0.4985.842
Key Statistics
Prev. Close
0.57
Open
0.57
Day's Range
0.498-0.57
52 wk Range
0.498-5.842
Volume
342.47K
Average Vol. (3m)
538.82K
1-Year Change
-88.7125%
Book Value / Share
1.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XAIR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.667
Upside
+1,569.88%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Beyond Air Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Beyond Air Inc SWOT Analysis


Market Dynamics
With a $2.00 price target from Roth Capital Partners, Beyond Air aims to disrupt Mallinckrodt's 70% market share in NO delivery systems
Regulatory Milestones
Explore Beyond Air's pursuit of label expansion for cardiac surgeries and CE mark in Europe, key catalysts for market growth and competitive positioning
Financial Hurdles
Despite promising technology, Beyond Air faces significant cash burn and lowered revenue projections, highlighting the challenges of commercialization
Innovative NO Delivery
Beyond Air's LungFit PH system generates nitric oxide from room air, potentially revolutionizing the $700 million global market for NO delivery systems
Read full SWOT analysis

Beyond Air Inc Earnings Call Summary for Q3/2026

  • Beyond Air (XAIR) reported 105% YoY revenue growth to $2.2M in Q3 FY2026, with gross profit turning positive and operating expenses reduced by 36%
  • Despite improvements, the company posted a $7.3M net loss ($0.85 per share), while maintaining a cash position of $17.8M as of December 31, 2025
  • Management secured $5M financing in January 2026 and established an equity line of credit up to $32M, extending cash runway into 2027
  • The company anticipates FDA approval for its second-generation LungFit PH system by end of 2026, focusing on commercial execution and global expansion
  • XAIR stock rose 2.94% in premarket trading following the earnings announcement, reflecting cautious investor optimism despite ongoing profitability challenges
Last Updated: 02/13/2026, 09:00 AM
Read Full Transcript

Compare XAIR to Peers and Sector

Metrics to compare
XAIR
Peers
Sector
Relationship
P/E Ratio
−0.2x−3.5x−0.5x
PEG Ratio
0.000.010.00
Price / Book
0.7x1.4x2.6x
Price / LTM Sales
0.8x2.7x3.2x
Upside (Analyst Target)
-36.2%47.6%
Fair Value Upside
Unlock12.7%6.1%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8.667
(+1,569.88% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Hold---MaintainMar 26, 2026
Jones Trading
Buy2.00+285.36%6.00MaintainFeb 19, 2026
Rodman & Renshaw
Buy5.00+863.39%-New CoverageJan 20, 2026
Jones Trading
Buy6.00+1,056.07%12.00MaintainNov 11, 2025
Piper Sandler
Buy5.00+863.39%20.00MaintainAug 13, 2025

Earnings

Latest Release
Feb 13, 2026
EPS / Forecast
-0.85 / -0.08
Revenue / Forecast
2.19M / 3.97M
EPS Revisions
Last 90 days

XAIR Income Statement

People Also Watch

0.168
CXAI
+1.88%
3.36
BATL
+0.15%
3.85
LFMD
+2.12%
34.04
CWCO
-0.09%
1.71
NXTT
+5.56%

FAQ

What Is the Beyond Air (XAIR) Stock Price Today?

The Beyond Air stock price today is 0.519 USD.

What Stock Exchange Does Beyond Air Trade On?

Beyond Air is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Beyond Air?

The stock symbol for Beyond Air is "XAIR."

What Is the Beyond Air Market Cap?

As of today, Beyond Air market cap is 5.580M USD.

What Is Beyond Air's Earnings Per Share (TTM)?

The Beyond Air EPS (TTM) is -5.065.

When Is the Next Beyond Air Earnings Date?

Beyond Air will release its next earnings report on Nov 10, 2025.

From a Technical Analysis Perspective, Is XAIR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Beyond Air Stock Split?

Beyond Air has split 2 times.

How Many Employees Does Beyond Air Have?

Beyond Air has 61 employees.

What is the current trading status of Beyond Air (XAIR)?

As of Apr 15, 2026, Beyond Air (XAIR) is trading at a price of 0.519 USD, with a previous close of 0.570 USD. The stock has fluctuated within a day range of 0.498 USD to 0.570 USD, while its 52-week range spans from 0.498 USD to 5.842 USD.

What Is Beyond Air (XAIR) Price Target According to Analysts?

The average 12-month price target for Beyond Air is 8.667 USD, with a high estimate of 14 USD and a low estimate of 2 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +1,569.88% Upside potential.

What Is the XAIR Premarket Price?

XAIR's last pre-market stock price is 0.566 USD. The pre-market share volume is 40,110.000, and the stock has decreased by -0.004, or -0.700%.

What Is the XAIR After Hours Price?

XAIR's last after hours stock price is 0.542 USD, the stock has decreased by -0.028, or -4.910%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.